Pandion’s keyword is immunomodulation, not immunosuppression. “I think that has really resonated with many of the investors,” Coyle adds. Pandion is also working on drugs for autoimmune liver diseases and is interested in type 1 diabetes, kidney disease, and autoimmune diseases of the skin. “The platform and the molecules we are building are very novel and unique, but we are combining it with well-established and well-known biology,” Coyle says. The same immunomodulation strategy could be used to design drugs to prevent rejection of organ transplants. Pandion’s series A investors include Polaris Partners, Versant Ventures, Roche Venture Fund, and BioInnovation Capital. The firm is currently headquartered in LabCentral, a shared space for over 30 biotech start-ups in the Cambridge, Mass., biotech hub Kendall Square.
by Ryan Cross |
January 18, 2018